Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Impel Pharmaceuticals Inc. (IMPL)

9.22   -0.1 (-1.07%) 07-02 18:56
Open: 9.28 Pre. Close: 9.32
High: 9.83 Low: 9.1
Volume: 49,509 Market Cap: 214(M)
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.84 - 9.89 9.89 - 9.94
Low: 8.98 - 9.04 9.04 - 9.09
Close: 9.13 - 9.22 9.22 - 9.3

Technical analysis

as of: 2022-07-01 4:22:53 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 12.51     One year: 14.62
Support: Support1: 8.16    Support2: 6.57
Resistance: Resistance1: 10.71    Resistance2: 12.51
Pivot: 8.97
Moving Average: MA(5): 9.31     MA(20): 8.86
MA(100): 7.24     MA(250): 9.87
MACD: MACD(12,26): 0.5     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 50.4     %D(3): 51.2
RSI: RSI(14): 58.3
52-week: High: 34.75  Low: 5.71
Average Vol(K): 3-Month: 85 (K)  10-Days: 143 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IMPL ] has closed below upper band by 33.8%. Bollinger Bands are 31.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 01 Jul 2022
Impel Pharmaceuticals to Present at HC Wainwright Global Investment Conference - GuruFocus.com

Thu, 30 Jun 2022
Impel Pharmaceuticals (NASDAQ:IMPL) Stock Price Up 2.4% - Defense World

Thu, 30 Jun 2022
Healthcare ERP Consulting Services Market Growth Highly Driven by the Rising Demand for Cloud Implementat - Benzinga

Wed, 29 Jun 2022
Impleum (IMPL), Moderate Volatility and Rising Wednesday: Is it Time to Cash Out? - InvestorsObserver

Tue, 28 Jun 2022
Impel Pharmaceuticals (NASDAQ:IMPL) delivers shareholders 15% return over 1 year, surging 15% in the last week alone - Simply Wall St

Mon, 27 Jun 2022
Neutral-Rated Impleum (IMPL) Falls Monday to $0.0002068612357 - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 23 (M)
% Held by Insiders 9.9e+006 (%)
% Held by Institutions 1.1 (%)
Shares Short 515 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.04e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -10
Return on Assets (ttm) 701.5
Return on Equity (ttm) -81.3
Qtrly Rev. Growth 668000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.6
Qtrly Earnings Growth -7.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -66 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 2334.38
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 616990
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.